Teva releases new drug bioequivalent to Imitrex

NORTH WALES, Pa. Teva Pharmaceuticals on Monday announced the availability of sumatriptan succinate tablets, which is bioequivalent to GlaxoSmithKline’s Imitrex tablets and indicated for the treatment of migraines.

Sales of Imitrex totaled $1 billion in 2008, according to GlaxoSmtihKline reports.

Sumatriptan Succinate Tablets are available in 25 mg, 50 mg and 100 mg strengths.